AnaptysBio Stock Analysis

ANAB
 Stock
  

USD 27.93  0.65  2.38%   

The current bullish price patterns experienced by current AnaptysBio shareholders could raise concerns from investors as the firm is trading at a share price of 27.93 on 435,931 in volume. The company directors and management have been very successful in rebalancing the firm assets at opportune times to take advantage of market volatility in November. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.02. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from AnaptysBio partners.
Please continue to Trending Equities.
  
The AnaptysBio stock analysis report makes it easy to digest most publicly released information about AnaptysBio and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. AnaptysBio Stock analysis module also helps to analyze the AnaptysBio price relationship with some important fundamental indicators such as market cap and management efficiency.

AnaptysBio Stock Analysis Notes

About 100.0% of the company shares are held by institutions such as insurance companies. The book value of AnaptysBio was presently reported as 9.79. The company recorded a loss per share of 2.76. AnaptysBio had not issued any dividends in recent years. AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Anaptysbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. For more info on AnaptysBio please contact Hamza Suria at 858 362 6295 or go to https://www.anaptysbio.com.

AnaptysBio Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. AnaptysBio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding AnaptysBio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
AnaptysBio has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 63.17 M. Net Loss for the year was (57.8 M) with loss before overhead, payroll, taxes, and interest of (35.32 M).
AnaptysBio currently holds about 442.15 M in cash with (45.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66.
AnaptysBio has a frail financial position based on the latest SEC disclosures
Over 100.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Despite shrinking by US66m in the past week, AnaptysBio shareholders are still up 137 percent over 3 years - Simply Wall St

AnaptysBio Upcoming and Recent Events

Earnings reports are used by AnaptysBio to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AnaptysBio previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

AnaptysBio SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. AnaptysBio prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that AnaptysBio investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial AnaptysBio specific information freely available to individual and institutional investors to make a timely investment decision.
12th of September 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Entry into a Material Definitive Agreement
View
9th of September 2022
Unclassified Corporate Event
View
31st of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
15th of August 2022
Unclassified Corporate Event
View
8th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
24th of June 2022
Submission of Matters to a Vote of Security Holders
View
10th of May 2022
Unclassified Corporate Event
View
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

AnaptysBio Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 770.21 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AnaptysBio's market, we take the total number of its shares issued and multiply it by AnaptysBio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

AnaptysBio Profitablity

AnaptysBio's profitability indicators refer to fundamental financial ratios that showcase AnaptysBio's ability to generate income relative to its revenue or operating costs. If, let's say, AnaptysBio is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, AnaptysBio's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of AnaptysBio's profitability requires more research than a typical breakdown of AnaptysBio's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(15.09) (16.28) 
Return on Average Assets(10.91) (11.77) 
Return on Average Equity(15.35) (16.56) 
Return on Invested Capital(0.54) (0.55) 
Return on Sales(0.92) (0.99) 

Management Efficiency

The entity has return on total asset (ROA) of (0.1404) % which means that it has lost $0.1404 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.4079) %, meaning that it created substantial loss on money invested by shareholders. AnaptysBio management efficiency ratios could be used to measure how well anaptysbio manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2022, Return on Investment is expected to decline to -16.28. In addition to that, Return on Average Assets is expected to decline to -11.77. AnaptysBio Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 643.07 Million. The current year Current Assets is expected to grow to about 597.6 M, whereas Assets Non Current are forecasted to decline to about 73.8 M.
Last ReportedProjected for 2022
Book Value per Share 12.99  10.93 
Enterprise Value over EBIT(11.00) (11.87) 
Enterprise Value over EBITDA(11.50) (12.40) 
Price to Book Value 2.68  2.80 
Tangible Assets Book Value per Share 23.44  20.62 
Enterprise Value640.4 M763 M
Tangible Asset Value643.1 M541.2 M

Technical Drivers

As of the 2nd of December, AnaptysBio shows the mean deviation of 2.34, and Risk Adjusted Performance of 0.1309. AnaptysBio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for AnaptysBio, which can be compared to its rivals. Please confirm AnaptysBio mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and information ratio to decide if AnaptysBio is priced correctly, providing market reflects its regular price of 27.93 per share. Given that AnaptysBio has jensen alpha of 0.1304, we suggest you to validate AnaptysBio's prevailing market performance to make sure the company can sustain itself at a future point.

AnaptysBio Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. AnaptysBio middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for AnaptysBio. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

AnaptysBio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AnaptysBio insiders, such as employees or executives, is commonly permitted as long as it does not rely on AnaptysBio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AnaptysBio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

AnaptysBio Technical and Predictive Indicators

AnaptysBio Forecast Models

AnaptysBio time-series forecasting models is one of many AnaptysBio's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AnaptysBio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About AnaptysBio Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how AnaptysBio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling AnaptysBio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as AnaptysBio. By using and applying AnaptysBio Stock analysis, traders can create a robust methodology for identifying AnaptysBio entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(89.93) (92.30) 
EBITDA Margin(85.78) (88.04) 
Gross Margin 0.90  0.89 
Profit Margin(91.49) (93.89) 

Current AnaptysBio Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. AnaptysBio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. AnaptysBio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
36.0Hold6Odds
AnaptysBio current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most AnaptysBio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand AnaptysBio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of AnaptysBio, talking to its executives and customers, or listening to AnaptysBio conference calls.
AnaptysBio Analyst Advice Details

AnaptysBio Stock Analysis Indicators

AnaptysBio stock analysis indicators help investors evaluate how AnaptysBio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading AnaptysBio shares will generate the highest return on investment. By understating and applying AnaptysBio stock analysis, traders can identify AnaptysBio position entry and exit signals to maximize returns.
Begin Period Cash Flow250516000.00
Logo U R LimglogosUSANAB.png
Common Stock Shares Outstanding27431000.00
Total Stockholder Equity356428000.00
Total Cashflows From Investing Activities38835000.00
Property Plant And Equipment Net21841000.00
Retained Earnings-321753000.00
Cash And Short Term Investments548097000.00
Retained Earnings Total Equity-321753000.00
Cash495729000.00
CodeANAB
Accounts Payable1741000.00
Net Debt-473269000.00
50 Day M A27.619
Total Current Liabilities16099000.00
Currency CodeUSD
Non Current Assets Total89194000.00
Common Stock Total Equity28000.00
Non Currrent Assets Other256000.00
Please continue to Trending Equities. Note that the AnaptysBio information on this page should be used as a complementary analysis to other AnaptysBio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for AnaptysBio Stock analysis

When running AnaptysBio price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Is AnaptysBio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine AnaptysBio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.